<DOC>
	<DOCNO>NCT00453934</DOCNO>
	<brief_summary>The primary objective study compare patient preference h-Patch delivery device insulin lispro compare either insulin pen needle syringe patient diabetes , either Type 1 Type 2 , stable multiple daily injection regimen . This assess use accepted preference scale .</brief_summary>
	<brief_title>Patient Preference h-Patch v . Pen Needle/Syringe Insulin Administration Device</brief_title>
	<detailed_description>Patients Type 1 Diabetes absolute deficiency insulin production benefit physiologic insulin replacement , define administration background mealtime insulin . More half patient Type 2 diabetes ( T2DM ) less 50 % beta cell function time diagnosis . Because , patient would also benefit physiologic delivery insulin . Currently , 4 injection per day require deliver various different available insulin physiologic manner . Valeritas develop h-Patch , device suitable make delivery basal bolus insulin effective , simple discrete . This study measure patient preference , glucose control safety h-Patch compare patient ' previous therapy . Patients previous therapy multiple daily injection deliver either pen needle syringe .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Diagnosis Type 1or Type 2 diabetes mellitus least year 2 . Stable insulin regimen least 3 month consist multiple daily injection human regular rapid act insulin meal time long intermediate acting insulin basal . In protocol multiple daily injection require least three injection daily . 3 . Total daily insulin dose 50 80 unit . 4 . If patient Type 2 , treat metformin and/or thiazolidinedione and/or sulfonylurea , diabetes drug include αglucosidase inhibitor , meglitinides , pramlintide exenatide , DPPIV 's exclude . 5 . HbA1c &gt; 7.0 % &lt; 9.0 % . 1 . Recurrent major hypoglycemia prolong unstable blood glucose control ( judged Investigator ) . 2 . Use diabetes drug include αglucosidase inhibitor , meglitinides , pramlintide , exenatide DPPIV inhibitor ( metformin and/or thiazolidinedione and/or sulfonylurea allow ) . 3 . Intend use concomitant drug therapy ( prescription overthecounter medication ) affect blood glucose level . 4 . Have use systemic glucocorticoid within 1 month prior Screening currently glucocorticoids . 5 . Have history drug alcohol abuse within 1 year prior Screening Visit . 6 . Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , neurological disease would , investigator 's opinion , preclude safe participation study . 7 . Have history major surgery , e.g . laparotomy , thoracotomy , open orthopedic procedure , etc . within 3 month prior Screening Visit . 8 . Evidence significant neuropsychiatric disease . 9 . Have participate medical , surgical , pharmaceutical investigational new drug/device study last 30 day ≤ 5 halflives investigational drug , whichever longer , prior Screening Visit . 10 . Blood donation 500 ml last 2 month prior Screening Visit . 11 . Evidence significant active hematological disease . 12 . Acute infection fever . 13 . Hemoglobin &lt; 10 g/dL ; AST , ALT ≥ 1.5 time upper reference limit Screening . 14 . Uncontrolled treated/untreated hypertension ( systolic blood pressure &gt; 155 mmHg diastolic blood pressure &gt; 90 mmHg ) . 15 . History proliferative retinopathy maculopathy require acute treatment 16 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation . 17 . Any condition Investigator and/or Sponsor feel would interfere trial participation evaluation result 18 . Pregnancy , breastfeeding , intention become pregnant female patient childbearing potential .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Physiologic Insulin</keyword>
	<keyword>Basal Insulin</keyword>
	<keyword>Bolus Insulin</keyword>
	<keyword>Mealtime insulin</keyword>
	<keyword>Insulin patch</keyword>
	<keyword>Multiple daily injection</keyword>
</DOC>